{"id":"pramiracetam","rwe":[{"pmid":"24824701","year":"2014","title":"A study of the mechanisms for antiaggregant activity of pyrrolidone derivatives in rats with chronic hyperglycemia.","finding":"","journal":"Bulletin of experimental biology and medicine","studyType":"Clinical Study"},{"pmid":"22702111","year":"2012","title":"[Platelet hyperreactivity and antiaggregatory properties of nootropic drugs under conditions of alloxan-induced diabetes in rats].","finding":"","journal":"Eksperimental'naia i klinicheskaia farmakologiia","studyType":"Clinical Study"},{"pmid":"20166767","year":"2010","title":"Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders.","finding":"","journal":"Drugs","studyType":"Clinical Study"},{"pmid":"21202668","year":"2008","title":"Diisoprop-yl{2-[2-(2-oxopyrrolidin-1-yl)acetamido]eth-yl}ammonium hydrogen sulfate.","finding":"","journal":"Acta crystallographica. Section E, Structure reports online","studyType":"Clinical Study"},{"pmid":"14965012","year":"2003","title":"[Experience in the application of pramistar, a new nootropic preparation, in the treatment of memory disorders in patients with cerebrovascular pathology].","finding":"","journal":"Likars'ka sprava","studyType":"Clinical Study"}],"tags":[{"label":"pramiracetam","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"N06BX16","category":"atc"},{"label":"Active","category":"status"},{"label":"Memory impairment","category":"indication"},{"label":"Senile dementia","category":"indication"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"amacetam","offLabel":[],"synonyms":["pramiracetam hydrochloride","pramiracetam HCl","pramistar","pramiracetam","amacetam","vinpotropil","pramiracetam sulfate","amacetam sulphate"],"timeline":[],"approvals":[],"brandName":"Amacetam","ecosystem":[{"indication":"Memory impairment","otherDrugs":[],"globalPrevalence":null},{"indication":"Senile dementia","otherDrugs":[{"name":"epicriptine","slug":"epicriptine","company":""}],"globalPrevalence":null}],"mechanism":{"modality":"Small Molecule","drugClass":"pramiracetam","explanation":"Think of your brain like a computer. Pramiracetam helps your brain's 'computer chips' (neurons) communicate more efficiently with each other, allowing you to process and store information better. This can lead to improved memory and concentration.","oneSentence":"Pramiracetam works by increasing the activity of certain neurotransmitters in the brain, such as acetylcholine, to enhance memory and cognitive function.","technicalDetail":"Pramiracetam is a cholinergic agent that acts as a positive allosteric modulator of the nicotinic acetylcholine receptor, increasing the release of acetylcholine and other neurotransmitters involved in memory and cognitive function."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2234","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=PRAMIRACETAM","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:24:08.595455","biosimilars":[],"competitors":[],"genericName":"pramiracetam","indications":{"approved":[{"name":"Memory impairment","source":"DrugCentral","snomedId":386807006,"regulator":"FDA"},{"name":"Senile dementia","source":"DrugCentral","snomedId":15662003,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"4449F8I3LE","CHEBI":"CHEBI:135110","INN_ID":"5054","UMLSCUI":"C0071809","ChEMBL_ID":"CHEMBL159776","KEGG_DRUG":"D05593","DRUGBANK_ID":"DB13247","PUBCHEM_CID":"51712","SECONDARY_CAS_RN":"75733-50-5","MESH_SUPPLEMENTAL_RECORD_UI":"C038438"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":40,"therapeuticAreas":["Neuroscience"],"atcClassification":{"source":"DrugCentral","atcCode":"N06BX16","allCodes":["N06BX16"]},"biosimilarFilings":[],"recentPublications":[{"date":"2014 Apr","pmid":"24824701","title":"A study of the mechanisms for antiaggregant activity of pyrrolidone derivatives in rats with chronic hyperglycemia.","journal":"Bulletin of experimental biology and medicine"},{"date":"2012","pmid":"22702111","title":"[Platelet hyperreactivity and antiaggregatory properties of nootropic drugs under conditions of alloxan-induced diabetes in rats].","journal":"Eksperimental'naia i klinicheskaia farmakologiia"},{"date":"2010 Feb 12","pmid":"20166767","title":"Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders.","journal":"Drugs"},{"date":"2008 May 30","pmid":"21202668","title":"Diisoprop-yl{2-[2-(2-oxopyrrolidin-1-yl)acetamido]eth-yl}ammonium hydrogen sulfate.","journal":"Acta crystallographica. Section E, Structure reports online"},{"date":"2003 Dec","pmid":"14965012","title":"[Experience in the application of pramistar, a new nootropic preparation, in the treatment of memory disorders in patients with cerebrovascular pathology].","journal":"Likars'ka sprava"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Amacetam, also known as Pramiracetam, is a small molecule drug in the pramiracetam class. It is used to treat memory impairment and senile dementia, although its exact target is unknown. The commercial status of Amacetam is unclear, and it is not FDA-approved. Pramiracetam is a nootropic agent that has been shown to improve memory and cognitive function in various studies. Further research is needed to fully understand its safety and efficacy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":false,"score":2}}